Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Sold by Farther Finance Advisors LLC

Farther Finance Advisors LLC decreased its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 9.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,614 shares of the specialty pharmaceutical company’s stock after selling 1,064 shares during the quarter. Farther Finance Advisors LLC’s holdings in Collegium Pharmaceutical were worth $304,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently modified their holdings of the company. JPMorgan Chase & Co. lifted its holdings in shares of Collegium Pharmaceutical by 173.6% during the third quarter. JPMorgan Chase & Co. now owns 277,204 shares of the specialty pharmaceutical company’s stock worth $10,711,000 after purchasing an additional 175,892 shares during the period. Penserra Capital Management LLC acquired a new stake in shares of Collegium Pharmaceutical during the third quarter worth about $757,000. Barclays PLC lifted its holdings in shares of Collegium Pharmaceutical by 152.2% during the third quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company’s stock worth $2,899,000 after purchasing an additional 45,291 shares during the period. Sanctuary Advisors LLC lifted its holdings in shares of Collegium Pharmaceutical by 10.7% during the third quarter. Sanctuary Advisors LLC now owns 17,976 shares of the specialty pharmaceutical company’s stock worth $695,000 after purchasing an additional 1,731 shares during the period. Finally, FMR LLC lifted its holdings in shares of Collegium Pharmaceutical by 1,532.2% during the third quarter. FMR LLC now owns 37,752 shares of the specialty pharmaceutical company’s stock worth $1,459,000 after purchasing an additional 35,439 shares during the period.

Collegium Pharmaceutical Trading Up 0.5 %

Shares of NASDAQ:COLL opened at $29.82 on Wednesday. The company has a market capitalization of $938.91 million, a PE ratio of 12.85 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a 12-month low of $27.28 and a 12-month high of $42.29. The business has a 50 day moving average of $30.89 and a two-hundred day moving average of $32.81. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.54 by $0.09. The business had revenue of $181.95 million during the quarter, compared to analysts’ expectations of $179.68 million. Collegium Pharmaceutical had a return on equity of 104.67% and a net margin of 14.78%. As a group, analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Activity

In other news, EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The stock was sold at an average price of $30.00, for a total value of $67,650.00. Following the completion of the sale, the executive vice president now directly owns 124,421 shares in the company, valued at $3,732,630. The trade was a 1.78 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the business’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $28.08, for a total value of $1,123,200.00. Following the sale, the executive vice president now owns 154,204 shares of the company’s stock, valued at $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 109,193 shares of company stock worth $3,243,594 over the last three months. 3.98% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently commented on the company. Needham & Company LLC raised Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 target price for the company in a report on Friday, January 10th. HC Wainwright reissued a “buy” rating and issued a $50.00 price target on shares of Collegium Pharmaceutical in a report on Friday, January 10th. Finally, Piper Sandler decreased their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.